Latest Breaking News On - Cadila healthcare limited zydus - Page 2 : comparemela.com
Global Biopharmaceutical Markets 2021-2026 - Focus on mAB, Recombinant Growth Factors, Purified Proteins, Proteins, Hormones, Vaccines, Synthetic Immunomodulators, Enzymes, & Cell and Gene Therapies
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Zydus partners with CHEMI of Italy to launch Enoxaparin Sodium Injection in the United States
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
EMA grants Orphan Drug Designation to Zydus Saroglitazar Mg
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
April 23, 2021
Company claims the treatment reduces the hours of supplemental oxygen in the patients Cadila Healthcare Limited (Zydus Cadila) has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults.
Announcing the development, the company informed that the single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients.
“When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications,” it said.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional set-up.
Zydus Cadila seeks DCGI nod for use of PegiHep in Covid-19 treatment
April 05, 2021
Phase-3 clinical trials showed promising results in treating Covid-19
In what could be termed a major breakthrough in the disease management of Covid-19, drug major Cadila Healthcare Limited (Zydus Cadila) has said that initial Phase-III clinical trials of Pegylated Interferon Alpha 2b, PegiHep, showed promising results in the treatment of the novel coronavirus.
The interim results indicate that PegIFN, when administered early on, could help patients recover faster, avoiding many of the complications seen in the advanced stages of the disease.
The company has sought the Drugs Controller General of India’s approval for the use of Pegylated Interferon alpha-2b in treating Covid-19 in India. Pegylated Interferon alpha-2b, or PegiHepTM, is an approved drug in India and is being re-purposed for the treatment of Covid-19.